Global Pathogen Surveillance Network (GPSN): Distributed Real-Time Sequencing and Reporting at the Point of Care
Description
Rebuild global disease surveillance as a distributed network rather than a centralized system: deploy sequencing capacity (currently $300-500 per genome, dropping to <$50 by 2028) directly to district hospitals and health clinics in 100 priority countries.
Link these sequencing hubs via a real-time data network (modeled on GISAID + a new standardized reporting protocol) that pushes pathogen sequence data to a global dashboard within 24 hours of sample collection — not weeks. Core components: (1) Hardware deployment: 500 nanopore sequencers ($8K each) to district hospitals in Sub-Saharan Africa, South Asia, and Southeast Asia.
(2) Training: 2,000 laboratory technicians trained to run sequencing and interpret results (6-month programs delivered locally). (3) Data integration: A WHO-hosted real-time surveillance dashboard that aggregates sequences, clinical metadata, and early alert signals from all reporting sites.
(4) Legal framework: Burden-sharing agreements that guarantee countries reporting novel pathogens early receive immediate access to diagnostics and medical countermeasures — removing the incentive to conceal outbreaks.
Implementation Pathway
Phase 1 (2026–2027)
- • Deploy sequencers to 100 district hospitals in 20 countries
- • Technician training programs operational in 15 countries
- • Real-time surveillance dashboard live with 50+ reporting sites
Phase 2 (2027–2030)
- • 400 sequencing sites operational across Sub-Saharan Africa, South Asia, SE Asia
- • GPSN processes 80% of outbreak-relevant samples from priority countries within 24 hours
- • Integration with national health ministries and WHO emergency response protocols
Phase 3 (2030+)
- • 1000 sequencing sites globally
- • GPSN becomes primary surveillance infrastructure for pandemic threat detection
Required Resources
Impact Analysis
Overall Net Impact
Combined analysis across all timeframes
Short-term
0-2 years
No benefits identified
No harms identified
Mid-term
3-10 years
No benefits identified
No harms identified
Long-term
10+ years
No benefits identified
No harms identified